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African Swine Fever (ASF) is an important contagious haemorrhagic viral disease affecting swine whose notification
is mandatory due to its high mortality rates and the great sanitary and socioeconomic impact it has on international
trade in animal and swine products.
This disease only affects porcine species, both wild and domestic, and produces a variety of clinical signs such
as fever and functional disorders of the digestive and respiratory systems. Lesions are mainly characterized by
congestive-haemorrhagic alterations. ASF epidemiology varies significantly between countries, regions and
continents, since it depends on the characteristics of the virus in circulation, the presence of wild hosts and
reservoirs, environmental conditions and human social behaviour. Furthermore, a specific host will not necessarily
always play the same active role in the spread and maintenance of ASF in a particular area.
Currently, ASF is endemic in most sub-Saharan African countries where wild hosts and tick vectors (Ornithodoros) play
an important role acting as biological reservoirs for the virus. In Europe, the disease has been endemic since 1978 on
the island of Sardinia (Italy) and since 2007, when it was first reported in Georgia, in a number of Eastern European
countries. It is also endemic in certain regions of the Russia Federation, where domestic pig and wild boar populations
are widely affected. By contrast, in the affected eastern European Union (EU) countries where ASF is currently as
epidemic, the on-going spread of the disease affects mainly wild boar populations located in restricted areas and,
to a much less extent, domestic pigs. Unlike most livestock diseases, no vaccine or specific treatment is currently
available for ASF. Therefore, disease control is mainly based on early detection and the application of strict sanitary and
biosecurity measures. Epidemiology of ASF is very complex by the existence of different virus circulating, reservoirs and
a number of scenarios, and the on-going spread of the disease through Africa and Europe. Survivor pigs can remain
persistently infected for months which may contribute to virus transmission and thus the spread and maintenance of
the disease, thereby complicating attempts to control it.
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Control strategiesIntroduction
African swine fever (ASF) is one the most important of all
swine diseases due to its significant sanitary and socioeco-
nomic consequences. Infected animals show a wide variety
of clinical forms and lesions that vary in terms of the viru-
lence of the virus and the immunological characteristics of
the host. Acute forms are predominant at the beginning of* Correspondence: arias@inia.es
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(http://creativecommons.org/publicdomain/zeoutbreaks in disease-free areas resulting in high mortality
rates of up to 95–100 %. Figure 1 Once established, the
disease progresses towards its acute and subacute clinical
forms that are sustained over time, although other clinical
forms (chronic and subclinical or unapparent) will eventu-
ally evolve in regions where the disease is endemic.
European wild boar (Sus scrofa) and feral pigs are
very susceptible to the disease and exhibit similar clin-
ical signs and lethality to domestic pigs. By contrast, in-
fected wild African Suidae develop subclinical and
asymptomatic long term persistent infections, acting as
virus reservoirs [1]. Figure 2 Soft ticks of the genusle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Clinical signs of acute form of ASF (source: EURL, INIA-CISA,
Valdeolmos, Madrid, Spain). Pigs affected by acute form of ASF
showing prostration and reddening of the skin at the tips of ears
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for the virus [2, 3].
ASF is endemic in most sub-Saharan countries. Since
it was introduced in 2007 into Eastern Europe it has af-
fected the Caucasus region and the Russia Federation,
where it now exists as a large-scale epidemic in domestic
pig and wild boar populations in two endemic zones in
central and southern Russia [4, 5]. This situation, to-
gether with the recent incursions of the disease into the
European Union (Fig. 3) and its complexity, underlines
the need to clarify some of the important uncertainties
regarding the epidemiology of ASF – for example, how
the virus is transmitted and how virus-host interactionsFig. 2 Warthog (Phacochoerus africanus). Phacochoerus genera act as
the reservoirs of the ASFV in Africa without clinical symptoms.
Transmission and maintenance of ASFV can occur in a sylvatic
cycle involving warthogs and bushpigs as well as ticks of the
genus Ornithodorosare established-in order to implement effective control-
eradication strategies. The role of wild and domestic
hosts in the different scenarios, the importance of envir-
onmental, social and cultural factors, and the part played
by survivor pigs are just some of the important gaps in
our knowledge that need urgently to be filled. The
current situation of ASF in Africa and Europe is today a
major threat to the pig industry worldwide.
History
ASF was first detected in Kenya in 1909 following the
introduction into the country of European domestic
swine. It was reported as an acute haemorrhagic disease
with mortality rates of 100 % in domestic pigs [6, 7]. It
was then recognised that the disease had been present in
eastern and southern Kenya in wild hosts for a very long
time. Subsequently, it was detected in Central and West
Africa but was confined to sub-Saharan African coun-
tries until it first reported outside Africa in 1957 in
Lisbon (Portugal), from where it had spread from West
Africa. After two years silence, in 1960 the disease ap-
peared again in Lisbon and soon spread to the Iberian
Peninsula and other countries in Europe such as France
(1964), Italy (1967, 1969, 1983), Malta (1978), Belgium
(1985) and the Netherlands (1986). Various countries in
the Americas were also affected by ASF during this
period: Cuba (1971, 1980), Brazil (1978), the Dominican
Republic (1978) and Haiti (1979). In all these countries
the disease has been successfully eradicated, the excep-
tion being the island of Sardinia (Italy) (Fig. 4).
The virus
The causative agent of the disease, the ASF virus
(ASFV), is the only member of the Asfaviridae family,
genus Asfivirus [8] (Fig. 5). It is a complex enveloped
virus with icosahedral morphology consisting of four
concentric layers and a large double-stranded DNA mol-
ecule that ranges in length between isolates from about
170 to 193 kbp [9]. It contains a conserved central re-
gion of about 125 kb and two variable ends. The differ-
ences in genome length are largely due to the gain or
loss of members of the multigene families (MGF) located
in the left and right variable regions [9]. A full genome
sequencing of up to 16 virus isolates has recently been
completed [10–14]. The ASF viral DNA contains be-
tween 151 and 167 open reading frames (ORFs) encod-
ing 54 structural proteins and around 100 polypeptides
in the targeted infected cells, monocytes and macro-
phages [15, 16]. The major components of the viral cap-
sid, the protein p72, the two structural proteins p30
(p32) and p54 and the polyprotein pp62, have been iden-
tified as the most antigenic of the proteins that are re-
sponsible for the induction of antibodies after a natural
infection [17, 18]. However, despite the usefulness of
Fig. 3 ASF notifications in Eastern Europe (source: A. Rodríguez (INIA-CISA, Valdeolmos, Madrid, Spain). Geographic map showing notifications
of ASF in Eastern Europe since 2007 to July 2015. In green dot notifications in European wild boar. In yellow dot notifications in domestic
pigs. Source: OIE
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sufficient for developing antibody-mediated protection
against virus strains [19].
Inactivation of ASFV
Although ASFV is very resistant to inactivation in the
environment, many lipid solvents and commercial dis-
infectants based on phenolic and iodide compounds
are effective and can inactivate the virus at pH < 4 and
pH >11 [20].
The virus may persist for several weeks or months in
frozen, fresh or uncooked meat, as well as in salted dried
meat products [20]. By contrast, ASFV is inactivated in
cooked or canned hams when these products are heated
to 70 °C and in cured or processed products such as
Spanish cured pork products (e.g. serrano and Iberian
hams and shoulders) at day 122–140 of curing [21].
Virus genotyping
Recent studies have reported a classification of 32 ASFV
isolates in eight different serogroups based on a hemad-
sorption inhibition assay (HAI) with ASFV reference
immune antisera [22].However, despite conventional ASFV genotyping can-
not discriminate between viruses of different virulence,
it has been widely demonstrated throughout more than
10 years that the molecular characterization of small
conserved regions of the DNA genome is the most use-
ful tool for tracing the origin of ASFV during outbreaks
[23–39]. The current approach is based on the analysis
of the C-terminal end of gene B646L encoding the major
protein p72 [39], following by the sequencing of the
Central Variable Region (CVR) within the B602L gene,
or other several regions (e.g. E183L encoding p54 pro-
tein, CP204L encoding p30 protein), for distinguishing
between geographically and temporally constrained p72
genotype viruses [28–30, 33, 34, 36, 38]. This approach
has allowed identifying twenty-two different p72 geno-
types among virus isolates from East and South African
countries to date, whereas genotype I is predominant in
West Africa [35, 37]. Outside Africa, genotype I was the
only one found in Europe, America, and the Caribbean,
until the introduction of genotype II in 2007 into
Georgia in 2007 from East Africa (Fig. 6) [33]. Current
available molecular data derived by using standardized
genotyping procedures have indicated the presence of
Fig. 4 Geographic distribution of ASF worldwide. In red, countries in which ASF is currently present from 2010 to date. In grey, countries in which ASF
was reported in the past. In white, countries in which ASF has not been never reported
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dicating a single introduction in 2007 [23, 27]. A variable
region between genes characterized by the presence of
tandem repeat sequences (TRS), recently identified as
useful for subtyping gene identification, has revealed the
presence of two variants in genotype II amongst the vi-
ruses circulating in Eastern European countries since
2012 [23, 40].Fig. 5 Electron micrograph of ASFV (source, INIA-CISA, Valdeolmos,
Spain). By electronic microscopy, viral particles show an average diameter
of 200 nm. The virion is formed by several concentric structures with an
external hexagonal envelope. The main target cells for ASFV replication
are monocytes and macrophage cellsRoutes for virus entry, pathogenesis and transmission
The entrance of ASFV into pigs normally occurs either
orally or nasally, although other routes such as cutane-
ous, subcutaneous, via tick-bites or scarification have
also been reported. Traditionally, virus entrance into free
regions usually occurs as a result of uncooked pork
waste–especially from ships and aircraft–being fed to
pigs. Once the disease is established in an area, it mainly
spreads by direct contact between sick and healthy ani-
mals (domestic pigs and wild Suidae), recovered carrier
pigs and soft ticks or, for example, through indirect
transmission by lorries, at drinking and eating troughs,
via surgical and personal equipment, rodents, or other
farm animals [1].
ASF has an incubation period of 4–19 days. Clinical
course lasts for 4–5 days in acute infections or longer
in cases of the subacute forms of the disease. Usually,
peracute and acute forms appear at the beginning of
the epidemic, which is characterized by high lethality
and the rapid spread of outbreaks [41, 42]. Once the
disease is established as endemic in an area, a broad
range of clinical symptoms and clinical onsets are to
be expected, with an increasing number of subacute,
chronic and subclinical infections but with mortality
rates that decline over time. Infected animals can sur-
vive for several weeks and some even recover from
the infection and remain sub-clinically infected for a
period of time [41, 43–49]. In endemic zones, the
Fig. 6 Distribution of ASF virus genotypes (source: EURL, INIA-CISA, Valdeolmos, Madrid, Spain). Symbols represent the 22 AFSV genotypes determined
by partial B646L (p72) sequencing known to be in circulation within that country. Genotypes are indicated in roman numerals
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forms, sometimes due to the appearance of virus iso-
lates of moderate and low virulence that are more
difficult to recognize in the field. In these cases, the
infection may persist for several months with no par-
ticular obvious symptoms in infected animals other
than transient fever, stunting or emaciation, symptoms
that may even mimic certain other diseases [42, 45,
50–55].
Clinical symptoms and lesions
Unlike Classical Swine Fever (CSF), which mainly affects
young pigs, all age groups are equally susceptible to
ASF. ASFV strains are classified as of high, moderate orFig. 7 Clinical signs and lesions of acute form of ASF in a domestic pig exp
Eastern Europe (source: EURL, INIA-CISA, Valdeolmos, Madrid, Spain). a Necr
and c melenalow virulence [55–58]. Highly virulent strains are usually
responsible for the peracute and acute forms that pro-
voke high mortality rates that may reach 100 % within
4–9 days post-infection. In peracute ASF, affected ani-
mals may die suddenly 1–4 days after the onset of clin-
ical signs with no evident lesions in organs.
The acute form of the disease is usually characterized
by a febrile syndrome with erythema and cyanosis of the
skin (Fig. 7). Functional failures of internal organs, above
all of the digestive system, vomiting and haemorrhagic
diarrhoea may occur. Anorexia, cyanosis and incoordin-
ation may occur 1–2 days before death. Abortion in
pregnant sows has frequently been described. Internal
lesions are mainly characterized by hyperaemicerimentally infected with an ASFV genotype II isolate circulating in
otic areas on the skin surface, b subcutaneous haematomas in legs
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in the visceral lymph nodes, with an excess of natural
fluids in body cavities and spaces [55, 57, 59] (Figs. 8
and 9).
In subacute forms of the disease, a persistent or fluc-
tuating fever lasts for up to 20 days; during this time,
some pigs remain healthy, while others display the
symptoms described above for the acute form, albeit less
severely than normal. The mortality rates for subacute
forms are in the range 30–70 % usually after 20 dpi. The
subacute form is characterized by milder lesions than
those described for the acute form [55].
In the chronic form of ASF, clinical signs and lesions
are not specific but may persist for several months, giv-
ing rise to a range of conditions with symptoms such as
skin ulcers and arthritis, delayed growth, emaciation,
pneumonia and abortion. Overall, the clinical signs asso-
ciated with the chronic form do not resemble the typical
clinical picture of ASFV infections [7, 41, 43–45, 50, 55,
56, 60–62].
The role of survivor pigs
Survivor pigs, sub-clinically infected and chronically in-
fected, can remain persistently infected for months
which may contribute to virus transmission and play an
important role in disease persistence in endemic areas,
as well as in sporadic outbreaks and ASFV introductions
into disease-free zones [1, 48, 49, 63–65]. Studies of
virus persistence and the transmission of ASFV to sus-
ceptible animals are scarce. In vivo experiments using
European domestic pigs have revealed an infectious
period of moderately virulent virus isolates ranging from
20 to 40 days [66]. Other in vivo study of ASFV trans-
mission with a virus isolate of low virulence have shown
that recovered pigs are still able to transmit the virus to
naive populations three months after being infected [67].
Field studies performed in affected regions of Brazil andFig. 8 Gross lesions of acute form of ASF in a domestic pig experimentally
(source: EURL, INIA-CISA, Valdeolmos, Madrid, Spain). Spleen displaying hyp
red to black)the Iberian Peninsula (1979–1981) have revealed that
3.5 % and 0.6 % of new outbreaks are thought to be
caused by seropositive domestic pigs that have survived
the initial infection [43, 47, 65]. Recent observations in
endemic regions of East Africa such as Tanzania have es-
timated the presence of asymptomatic seropositive pigs
at 3.72 %, even one year after the occurrence of an ASF
outbreak [68]. Similar findings have been reported from
Kenya and Uganda [69, 70].
The persistence of viruses in tissues of infected ani-
mals for up to six months has been repeatedly proven
which indicates the length of the risk period during
which the disease can be contracted from infected
carcasses [51, 52, 71, 72].
Some considerations regarding ASF in affected regions
A)A brief view of the disease in Africainfect
eremicThe pig population in Africa is concentrated in sub-
Saharan Africa, mostly on small-scale family farms.
AU-IBAR-FAO data obtained in 2013 show it
consisted of around 32 million heads distributed
regionally as follows: 42, 32, 14 and 12 % in western,
southern, eastern, and central Africa, respectively [73].
ASF was present in most of these areas in the past.
However, from 1995 onwards, a significant
increase in the number of ASF outbreaks occurred
in sub-Saharan regions and new countries were
affected. The disease spread extensively particularly
in western regions and on some islands previously
free of the disease, such as Madagascar and
Mauritius. This upsurge of the disease in Africa,
coupled with a lack of awareness, were crucial
factors in the spread of the virus beyond Africa
and into the Caucasus region (Georgia, Europe) in
April 2007. As well, the disease recently re-emerged
in 2014 and 2015 in the Ivory Coast and on Capeed with an ASFV genotype II isolate circulating in Eastern Europe
splenomegaly (enlarged with rounded edges, friable and dark
Fig. 9 Gross lesions of acute form of ASF in a domestic pig experimentally infected with an ASFV genotype II isolate circulating in Eastern Europe
(source: EURL, INIA-CISA, Valdeolmos, Madrid, Spain). Lymph nodes (LN) enlarged edematous and completely hemorrhagic similar to a blood clot,
mainly gastro hepatic and kidney LNs
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notifications).
To date, ASF is endemic in more than 23 countries
in sub-Saharan Africa. The transmission of the ASF
virus occurs via a number of complex epidemiological
scenarios that depend on the presence of the presence
of reservoirs, wild Suidae and soft ticks (Ornithodoros
moubata), and domestic pig hosts, certain types of
animal production and husbandry, and social
behaviour. ln eastern and southern Africa, where
all the 22 ASFV genotypes are known to circulate,
the disease is maintained by the concurrent existence
of transmission cycles involving asymptomatic wild
Suidae (Phacochoerus and Potamochoerus spp.), soft
ticks (O. porcinus) and domestic pigs. By contrast,
the pig to pig transmission cycle is predominant in
western Africa, where no ticks have been reported
to date [1, 37, 49].
The clinical picture of ASF reported in domestic
pigs in African regions shows acute and sub-acute
forms of the disease, associated with both virulent
and moderately virulent virus isolates. In these animals,
the viraemia starts few days after infection and
antibody response can be usually detected from the
second week post-infection onwards [62, 71]. In
addition, the presence of subacute-to-unapparent
clinical signs in local ‘indigenous’ domestic breeds
in regions of East African has also been described in
recent years. An in vivo experiment in both, local
indigenous and European breeds, showed local
indigenous pigs displayed a clear significant delay in
the onset of ASF infection compared to the European
breeds of pig, as well as an unclear, unspecific and
non-pathognomonic clinical picture of the disease.High viraemia was detected in both groups, and a
significant delay in the detectable antibody response
was also observed, results that in some cases were
absent in the local breed when compared to
European breed [74].
B) A brief view of the disease in Eastern Europe
Once introduced into the Caucasus in 2007, ASF
spread rapidly into the neighbouring countries of
Armenia and Azerbaijan, and then into southwest
Russia, from where, due to the lack of any effective
control measures, it continued its spread into the
Ukraine (2012) and Belarus (2013). At present, a
clear endemic pattern in both domestic pigs and
wild boars has been identified in two regions of
southwest and central Russia [5].
The first notification of ASF in an EU country
occurred in January 2014 in wild boar from
Lithuania. A month later, new cases of ASF were
detected in Poland and later in Latvia and Estonia.
To date (09/2015), nearly a thousand of ASF
notifications in wild boar and in lesser extent in
domestic pigs (around 75, mostly in backyard farms)
have been reported, in many cases in the eastern
regions of the above-mentioned countries that
border on Belarus and Russia. It is highly likely that
the disease was introduced into the EU in 2014 by
wild boar entering Lithuania, Poland and Latvia,
from Belarus, or Estonia from Latvia [75].
The ASFV isolates circulating in Eastern Europe are
virulent viruses that induce acute forms of ASF with
high lethality in both domestic and wild animals
[59, 76–78]. Deaths usually occur in the second
week after infection. However, since the introduction
of the virus into the Russian Federation in 2007 ASF
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domestic pig and wild boar populations, with two
recognized endemic zones in central and southern
parts of the Russian Federation [5]. Field and
experimental findings in Russia reveal the existence of
sero positive wild boar animals previously diagnosed
at the limit of the detection or negative when tested
with the ASF virological assays [79–81]. These data
suggest that, despite the virulent nature of current
ASFV circulating strains affecting East Europe, some
animals can survive for over a month and are able
to recover from the infection, even remaining
sub-clinically infected, and could become virus
carriers enabling the virus to persist and spread
amongst the porcine population [59, 67]. It has
been demonstrated that in areas where ASF becomes
endemic, increased numbers of subacute and
subclinical infections also occur, and that mortality
rates decline over time [43, 44]. This could be
related to the acquired immunity from previous
exposure to lower doses of virus, adaptation of the
virus to the host and/or the evolution to viruses
with reduced virulence which can emerge after many
years of circulation into the pig populations [1, 7].
It is important to note that, in contrast to Russia,
where domestic pigs play a major role in the
transmission of the disease [82, 83], to date in the
EU wild boar are the hosts that are causing greatest
concern. The ASF cases occurring in the wild boar
population demonstrate the epidemiological
complexity of the scenario and the inherent
difficulties in containing the propagation of the virus
in the regions bordering on Russia and Belarus. In
these countries, the disease is not being effectively
controlled and continued spill-over into bordering
regions is likely to occur as a result.Understanding ASFV infection dynamics on industrial pig
farms
Some outbreaks on pig farms have been particularly dra-
matic and thousands of animals have had to be slaugh-
tered. Therefore, it is worth analysing how ASFV
infections occur and what lessons should be learned
from such outbreaks. A good example occurred during
summer 2014 in the Ignalina region (Utena province) in
northeast Lithuania, 22 km from the frontier with
Belarus [84]. This outbreak occurred in an intensive in-
dustrial pig farm, with a closed cycle and very strict bio-
security measures, and had catastrophic consequences as
over 20,000 animals had to be sacrificed. As a result of
the observations it was demonstrated after its first entry
in a pig farm, the virus moves and spreads initially with-
out evident clinical signs of ASF. The first sign was the
sudden death of a few animals in the same shed, whichwas associated to other causes, such as poisoning. Fol-
lowing this initial infection, the virus multiplied resulting
in a second wave of infection within 12–14 days that
leads to many more deaths. This second–or even third–
wave affects more animals in the same area, and leads to
devastating waves of deaths a few days later in which
almost all the animals in the same stall die.
This information offers crucial insights: disease field
recognition should be one of the major pillars of early
disease detection. Therefore, tighter clinical controls
must be established. In high-risk areas, sudden deaths of
a few animals should not simply be attributed to com-
mon causes and should, instead, be treated with the up-
most seriousness. It is important to point out that
different evolution patterns of the ASFV infection can
be expected. The movement and the spread of the waves
of ASFV infection will depend on biosecurity conditions
and the type of production system, husbandry, manage-
ment and organization involved. A key element in pre-
vention – above all in areas at risk either due to their
proximity to infection sources or to trade routes – is to
heed even minimal clinical symptoms, i.e. fevers, when
they appear, even if they only affect just a few animals.
Periodical clinical checking must be carried out, along
with the implementation of strict biosecurity measures
based on available protocols designed to control the
movements of animals, staff and vehicles. The earlier the
disease is detected, the fewer the losses and the easier it
will be to halt the propagation of the virus to other
farms.
ASF Diagnosis
Early detection of the disease is required to implement
sanitary and biosecurity control measures in order to
prevent the spread of the disease [49]. However, ASF
clinical diagnosis is not easy due to (i) the wide range of
clinical forms and the disease’s complex epidemiology,
with a number of different scenarios, and (ii) the similar-
ity of its symptoms to those of other viral infections
such as CSF, PRRS, swine erysipelas, salmonella, Porcine
Dermatitis and Nephropathy Syndrome, as well as other
septicaemic conditions such as poisoning. Therefore,
rapid laboratory diagnosis is essential and it should in-
volve the detection and identification of the virus parti-
cles and the specific anti-ASFV antibodies. A good
laboratory diagnosis and interpretation provide relevant
information on infection dynamic that will be very help-
ful to deploy effective control–eradication programs
(Fig. 10). The techniques currently in use provide a
confident diagnosis of ASF in any epidemiological situ-
ation [85–89] (Fig. 11). The use of the most appropriate
diagnostic tools updated for all scenarios is critical for
successfully implementing effective control programs.
PCR tests are the first choice for early detection of the
Fig. 10 Dynamic of ASF infection (source: OIE WRL, UCM, Madrid, Spain and EURL, INIA-CISA, Valdeolmos, Madrid, Spain). The picture summarizes the ASF
virus appearance in blood and antibodies after an ASFV infection. In addition, it shows the lethality of the different forms of the clinical disease, which
ranges from acute to a subacute, as well as from recovered animals. Antibodies are detectable for a long period of time following the initial exposure
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such tests are fully sensitive to the low viraemia levels,
which can be most often evident in infected animals of
endemic zones. For antibody detection, it is important
to note that current ELISA tests have a limitedFig. 11 Summary of current available validated ASF Diagnosis tests (source
tests are available for ASF diagnosis. Since 2010 several new commercial tests h
companies mainly referred to new PCR commercial kit from Ingenasa, Life tech
Organisms (OIE, EU…)sensitivity in the case of low antibody titres and usu-
ally detect antibodies from 12–14 days post-infection.
Indirect Immunoperoxidase tests (IPT) and Indirect
Immunofluorescence tests (IIF) are very useful for de-
tecting specific antibodies, although they cannot be: EURL, INIA-CISA, Valdeolmos, Madrid, Spain). A significant number of
ave been incorporated in the market, and several others are coming from
nologies, or Quiagen that would require to be validated by International
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readily available tools for diagnosis have been identi-
fied, it is also necessary to apply a specific value to
each diagnostic test and bear in mind their limits in
the context of each epidemiological situation, i.e.
whether it is taking place in an ASF-free region or an
endemic zone, in case of an outbreak. If ASFV enters
a disease-free area, virus isolation should be carried
out to confirm the presence of the disease. Due to the
ASF characteristics and disease dynamics, it is essen-
tial that virus and antibody detection techniques be
performed in parallel by diagnostic laboratories to en-
sure a complete picture of the epidemiological situ-
ation on a day-to-day basis.
Vaccines
No vaccine currently exists to prevent and control ASF.
For over 40 years various different strategies have been
employed in the search for an effective vaccine for this
disease. Given the complexity of the virus, with genes in-
volved in the evasion of the immune response [90–92],
and the absence of an effective protection mediated by
neutralizing antibodies [93], the conventional formula-
tions of live and inactivated vaccines that work with the
majority of pathogens have not yet been efficient as pro-
tection against ASFV. Nevertheless, it is known that re-
covered pigs can be protected against subsequent
infections with related viruses, as well as partial protec-
tion can be achieved with attenuated and low virulent
isolates [62, 94, 95]. These data together the advances
on the molecular and biological characteristics of the
virus [11, 13], and on the immune mechanism that
could be involved in protection [92], have led to the de-
velopment of new promising vaccine candidates. Cur-
rently, a number of different approaches are under
study [96–100], the most promising of which are based
on stimulating the cytolytic CD8+ T-cell and antibody
response [92, 98, 99]. These strategies include the con-
struction of deletion mutants from virulent or moder-
ate to low virulent virus isolates, by deleting genes
involved in i.e replication, virulence, cellular transport
or innate immune response [96, 97, 100]. These vaccine
candidates are in a first assessment step, so studies for
safety, adverse reactions, potential persistence and
transmission in the field are far to be evaluated.
How to control the disease
Disease knowledge and epidemiological information is
crucial for controlling ASF in affected areas. Information
about the type of hosts involved, their location, and po-
tential role in virus transmission and spread, the bio-
logical characteristics of the circulating virus and the
clinical picture to be expected given the host affected, as
well as the environmental, social and cultural features ofthe disease site a definition of risk factors for ASFV
entrance and spreading in and specific area, are of major
importance and should be elucidated for the provision
of an effective control programme.
In areas with limited resources to fight against ASF,
education of veterinarians, producers, and farmers is a
major issue to maintain a regular clinical inspection of
animals as well as the reinforcement of preventive biose-
curity measures to guarantee the safe production and
marketing of pigs and pig as a means of optimizing con-
trol strategies based on risk reduction that would lessen
the laboratory costs of contingency and control plans.
Control-eradication strategies
Africa
Currently, regional initiatives exist that include specific
control programmes designed to reduce the impact of
ASF on the pig sector in Africa. As well, an initiative is
being prepared by AU-IBAR-FAO for the control of the
disease in eastern Africa. The main strategy is based in
controlling ASF in the affected areas and to prevent it
from being introduced into non-infected areas. Regional
governments and international organisms such as AU-
IBAR/FAO working groups are working on ways to
improve disease information, identify socio-economic
drivers, increase awareness amongst farmers, butchers
and other pig-sector stakeholders, strengthen the capaci-
ties of veterinary services in disease detection, diagnosis,
surveillance, management, contingency planning and
emergency response, and pinpoint priority actions and
opportunities for collaboration. Disease monitoring and
epidemio-surveillance systems are weak and data and in-
formation about ASF are mainly being generated by pas-
sive surveillance. To guide the establishment of a
national surveillance system for ASF, strategies should
be developed based on existing FAO and OIE guidelines.
The design of risk-based surveillance systems that take
into account risk factors for ASF occurrence and trans-
mission will maximize the efficiency and efficacy of the
system.
Eastern Europe
Non-EU countries are combating ASF and trying to pre-
vent the disease from spreading. However, few effective
results have been obtained so far and the disease con-
tinues to spread into neighbouring countries, mainly
along wild boar corridors, and other ways of virus trans-
mission could occur at any time.
In EU countries, the prevention measures imple-
mented when ASF first appeared in Eastern Europe in
2007 were initially based on strengthening surveillance
programmes. Subsequently, as ASF was progressing, a
revision of contingency plans in EU member states was
carried out that, along with the addition of new methods
Gallardo et al. Porcine Health Management  (2015) 1:21 Page 11 of 14to the existing preventive measures, enabled the virus to
be detected very quickly. As the situation got worse,
however, an increase in protection measures was also ex-
ecuted, which currently includes the disinfecting of vehi-
cles, stricter controls at border crossings, the suspension
of livestock markets, greater biosecurity on farms,
awareness-raising campaigns and tougher vigilance pro-
grammes [101–103]. This latter task currently involves
an increase in the number of diagnostic analyses of do-
mestic pigs and wild boar, the creation of buffer zones
aimed at reducing wild boar densities and limiting their
ability to cross frontiers, and, in some cases, the pre-
ventative slaughtering of pigs in backyard farms in high-
risk areas. Evidence of the EU’s capacity to control and
contain this disease is the success it has had on the island
of Sardinia, from where, despite its presence for two de-
cades, it has never crossed over onto the European main-
land. Right from the start of the outbreaks in the Eastern
European Union countries in 2014, the European Commis-
sion decided to apply the World Trade Organization’s
regionalization principle, in line with the OIE’s international
standards. Current control and eradication programmes in
the EU contain all the elements that should guarantee their
success. Awareness-raising, epidemiological information,
strict biosecurity and sanitary measures, coordination be-
tween all implicated parts, good communication between
sources of field information and diagnostic laboratories, ad-
vances in the resolution of problems and the deficiencies
that arise, the promotion of necessary epidemiological
research in affected areas, and so forth. Nevertheless, if
affected countries in Eastern Europe are unable to contain
the spread of the disease, the EU must be aware that
isolated wild boar cases will continue to occur in border
areas of the EU, and that they will have to be combated.
A worldwide threat
The risk of introduction of ASF into new regions is
likely to occur in a near future. The major threat is cur-
rently for the East Asian countries that maintain import-
ant trade and links with ASF endemic African countries,
although the risk coming from Eastern Europe bordering
countries is not a trivial matter. China, with the highest
pig population of the world, and a large proportion of
family and free ranging pigs, could encounter difficulties
in controlling ASF in case of an incursion into these
production systems. Nor should we forget the worldwide
trade and communications by roadways, planes and
ships place all regions, and continents at risk.
Conclusions
ASF is a very complex disease, with complex epidemi-
ology and many different scenarios in which certain
hosts, playing different roles, interact with a number of
different circulating virus isolates. Since no vaccine iscurrently available, prevention and control must be
based on early detection and strict sanitary measures.
Early detection should be based on rapid disease recogni-
tion in the field, followed by laboratory diagnosis, that it is
essential for disease control. Further knowledge of the dis-
ease is necessary for progress in prevention and control-
eradication strategies in Africa and Eastern Europe.
Continuing education of veterinary services, vets, producers
and hunters by training, awareness of the risk factors in-
volved in ASFV entrance and spread, virus-host interac-
tions, virus transmission mechanisms, improved knowledge
of the presence of vectors and reservoirs, the development
of risk maps and models for ASFV diffusion, and the as-
sessment of the role carrier animals play under different
scenarios are just some of the issues that must be tackled.
Without the pertinent information, the disease cannot be
fought. The current panorama indicates that – unfortu-
nately – we will not be able to ignore African swine fever
for some time yet. This is a worldwide threat and all coun-
tries must be adequately prepared.
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